Selected article for: "attenuated vector and candidate vaccine"
Author: Boulton, Stephen; Poutou, Joanna; Martin, Nikolas T.; Azad, Taha; Singaravelu, Ragunath; Crupi, Mathieu J.F.; Jamieson, Taylor; He, Xiaohong; Marius, Ricardo; Petryk, Julia; Tanese de Souza, Christiano; Austin, Bradley; Taha, Zaid; Whelan, Jack; Khan, Sarwat T.; Pelin, Adrian; Rezaei, Reza; Surendran, Abera; Tucker, Sarah; Brown, Emily E.F.; Dave, Jaahnavi; Diallo, Jean-Simon; Auer, Rebecca; Angel, D Jonathan B.; Cameron, William; Cailhier, Jean-Francois; Lapointe, Réjean; Potts, Kyle; Mahoney, Douglas J.; Bell, John C.; Ilkow, Carolina S.
Title: Single dose replicating poxvirus vector-based RBD vaccine drives robust humoral and T cell immune response against SARS-CoV-2 infection
  • Cord-id: 0k0ve471
  • Document date: 2021_10_20
    • ID: 0k0ve471
    Snippet: The coronavirus disease 2019 (COVID-19) pandemic requires the continued development of safe, long-lasting, and efficacious vaccines for preventative responses to major outbreaks around the world, and especially in isolated and developing countries. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we characterize a temperature-stable vaccine candidate (TOH-Vac1) that uses a replication-competent, attenuated vaccinia virus as a vector to express a membrane-tethered spike rec
    Document: The coronavirus disease 2019 (COVID-19) pandemic requires the continued development of safe, long-lasting, and efficacious vaccines for preventative responses to major outbreaks around the world, and especially in isolated and developing countries. To combat severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), we characterize a temperature-stable vaccine candidate (TOH-Vac1) that uses a replication-competent, attenuated vaccinia virus as a vector to express a membrane-tethered spike receptor binding domain (RBD) antigen. We evaluate the effects of dose escalation and administration routes on vaccine safety, efficacy, and immunogenicity in animal models. Our vaccine induces high levels of SARS-CoV-2 neutralizing antibodies and favorable T cell responses, while maintaining an optimal safety profile in mice and cynomolgus macaques. We demonstrate robust immune responses and protective immunity against SARS-CoV-2 variants after only a single dose. Together, these findings support further development of our novel and versatile vaccine platform as an alternative or complementary approach to current vaccines.

    Search related documents:
    Co phrase search for related documents
    • acute pneumonia and administration day: 1
    • acute respiratory syndrome and additional advantage: 1
    • acute respiratory syndrome and additional cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15
    • acute respiratory syndrome and additional challenge: 1, 2, 3, 4, 5
    • acute respiratory syndrome and adenovirus mrna: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and administer vaccine: 1
    • acute respiratory syndrome and administered dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and administration day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19
    • acute respiratory syndrome coronavirus and additional advantage: 1
    • acute respiratory syndrome coronavirus and additional cell: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • acute respiratory syndrome coronavirus and additional challenge: 1, 2, 3
    • acute respiratory syndrome coronavirus and adenovirus mrna: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome coronavirus and administer vaccine: 1
    • acute respiratory syndrome coronavirus and administered dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome coronavirus and administration day: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10
    • adenovirus mrna and administered dose: 1, 2